Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia

Crespo-Solis, 2018, Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA), Cancer Med, 7, 2423, 10.1002/cam4.1513 Boissel, 2018, Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?, Blood, 132, 351, 10.1182/blood-2018-02-778530 Rytting, 2017, Acute lymphoblastic leukemia in adolescents and young adults, Cancer, 123, 2398, 10.1002/cncr.30624 Haïat, 2011, Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol, Leuk Res, 35, 66, 10.1016/j.leukres.2010.04.002 Rytting, 2016, Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen, Am J Hematol, 91, 819, 10.1002/ajh.24419 El-Cheikh, 2017, Hyper-CVAD compared with BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. a retrospective single-center analysis, Clin Lymphoma Myeloma Leuk, 17, 179, 10.1016/j.clml.2016.11.002 Huguet, 2009, Pediatric-inspired therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: the GRAALL-2003 study, J Clin Oncol, 27, 911, 10.1200/JCO.2008.18.6916 Ribera, 2008, Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96, J Clin Oncol, 26, 1843, 10.1200/JCO.2007.13.7265 DeAngelo, 2015, Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia, Leukemia, 29, 526, 10.1038/leu.2014.229 Stock, 2019, A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403, Blood, 133, 1548, 10.1182/blood-2018-10-881961 Stock, 2008, What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies, Blood, 112, 1646, 10.1182/blood-2008-01-130237 Siegel, 2018, Pediatric-inspired treatment regimens for adolescents and young adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: a review, JAMA Oncol, 4, 725, 10.1001/jamaoncol.2017.5305 Siegel, 2018, Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: hyper-CVAD vs. pediatric-inspired regimens, Am J Hematol, 93, 1254, 10.1002/ajh.25229 Ramanujachar, 2006, Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols, Pediatr Blood Cancer, 47, 748, 10.1002/pbc.20776 Huguet, 2018, Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial, J Clin Oncol, 36, 2514, 10.1200/JCO.2017.76.8192 Lepretre, 2016, Pediatric-like acute lymphoblastic leukemia therapy in adults with lymphoblastic lymphoma: the GRAALL-LYSA LL03 study, J Clin Oncol, 34, 572, 10.1200/JCO.2015.61.5385 Ribera, 2014, J Clin Oncol, 32, 1595, 10.1200/JCO.2013.52.2425 Ruiz-Delgado, 2011, Outcome of adults with acute lymphoblastic leukemia treated with a pediatric-inspired therapy: a single institution experience, Leuk Lymphoma, 52, 314, 10.3109/10428194.2010.529202 Usvasalo, 2008, Acute lymphoblastic leukemia in adolescents and young adults in Finland, Haematologica, 93, 1161, 10.3324/haematol.12466 Thomas, 2010, Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome–negative precursor B-lineage acute lymphoblastic leukemia, J Clin Oncol, 28, 3880, 10.1200/JCO.2009.26.9456 Kantarjian, 2000, Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia, J Clin Oncol, 18, 547, 10.1200/JCO.2000.18.3.547 Boissel, 2003, Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials, J Clin Oncol, 21, 774, 10.1200/JCO.2003.02.053 de Bont, 2005, [Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols], Ned Tijdschr Geneeskd, 149, 400 Hallböök, 2006, Treatment outcome in young adults and children > 10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol, Cancer, 107, 1551, 10.1002/cncr.22189 Ramanujachar, 2007, Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials, Pediatr Blood Cancer, 48, 254, 10.1002/pbc.20749 López-Hernández, 2008, [Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs adult treatment protocol], Gac Med Mex, 144, 485 Hayakawa, 2014, Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group, Blood Cancer J, 4, e252, 10.1038/bcj.2014.72 Alacacioglu, 2014, Is the BFM regimen feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of BFM and hyper-CVAD chemotherapy in two centers, Chemotherapy, 60, 219, 10.1159/000375258 López-Hernández, 2016, [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type], Gac Med Mex, 152, 439 Quiroz, 2019, The emerging story of acute lymphoblastic leukemia among the Latin American population—biological and clinical implications, Blood Rev, 33, 98, 10.1016/j.blre.2018.08.002 Gómez-Almaguer, 2017, Acute leukemia characteristics are different around the world: the Mexican perspective, Clin Lymphoma Myeloma Leuk, 17, 46, 10.1016/j.clml.2016.09.003 Barrington-Trimis, 2015, Rising rates of acute lymphoblastic leukemia in Hispanic children: trends in incidence from 1992 to 2011, Blood, 125, 3033, 10.1182/blood-2015-03-634006 Díaz-Ruiz, 2015, [Analysis of clinical-biological features of adult acute lymphoblastic leukemia], Gac Med Mex, 151, 150 Brown, 2017, NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017, J Natl Compr Canc Netw, 15, 1091, 10.6004/jnccn.2017.0147 Howard, 2011, The tumor lysis syndrome, N Engl J Med, 364, 1844, 10.1056/NEJMra0904569 Konoplev, 2017, CRLF2-positive B-cell acute lymphoblastic leukemia in adult patients: a single-institution experience, Am J Clin Pathol, 147, 357, 10.1093/ajcp/aqx005 Jain, 2017, Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults, Blood, 129, 572, 10.1182/blood-2016-07-726588 Harvey, 2010, Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia, Blood, 115, 5312, 10.1182/blood-2009-09-245944 Harvey, 2010, Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome, Blood, 116, 4874, 10.1182/blood-2009-08-239681 Giebel, 2019, Bone Marrow Transplant, 54, 798, 10.1038/s41409-018-0373-4 Maury, 2016, Rituximab in B-lineage adult acute lymphoblastic leukemia, N Engl J Med, 375, 1044, 10.1056/NEJMoa1605085 Jabbour, 2020, Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome–negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial, Lancet Haematol, 7, e523, 10.1016/S2352-3026(20)30144-7 Rausch, 2020, Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management, Cancer, 126, 1152, 10.1002/cncr.32606